MEDICAGO
7.12.2020 13:32:51 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tula Technology Builds Global Momentum Expanding OEM and Tier 1 Engagements4.2.2026 08:00:00 CET | Press release
Provides 2026 business outlook with multiple start of production (SOP) targets in 2027 Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today provided a business update highlighting further technical progress across China and Europe as the Company advances towards global commercialization. In the fourth quarter of 2025, another Global Tier 1 completed DMD testing, achieving efficiency exceeding expectations. The Company also signed two additional memoranda of understanding, expanding engagement with OEMs and Tier 1 suppliers. In total, Tula is advancing six development programs towards a start of production (SOP) in 2027, with additional programs to follow. In China, Tula has recently signed two additional agreements – one with a Chinese OEM and another with a global Tier 1 supplier. The OEM has already begun dynamometer testing to confirm the DMD benefit, and upon meeting expectations, an over-the-air update adding DMD software into
LINVO AG Sponsors Fight Aids Cup 2026 in Monaco4.2.2026 07:00:00 CET | Press release
Football legends unite with royalty for HIV awareness at Stade Louis II When Leonardo Bonucci, Andriy Shevchenko and Clarence Seedorf lined up alongside Formula 1 star Charles Leclerc on January 24, 2026, it wasn't for a trophy - it was for a cause. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203762724/en/ LINVO AG serves as an Official Sponsor of the Fight Aids Cup Monaco 2026, uniting football legends for the global fight against HIV/AIDS. LINVO AG proudly sponsored Cirque FC at the sixth annual Fight Aids Cup, held at Monaco's iconic Stade Louis II. The charity match raised funds for Fight Aids Monaco, the HIV awareness foundation chaired by H.S.H. Princess Stéphanie. For over two decades, Fight Aids Monaco has worked to break down barriers surrounding HIV/AIDS - funding prevention programmes, supporting research, and providing direct assistance to those living with the disease. The Fight Aids Cup has become the fou
Murata’s Releases Technology Guide to Enhance Power Stability in AI-driven Data Centers4.2.2026 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has launched a new technology guide entitled: ‘Optimizing Power Delivery Networks for AI Servers in Next-Generation Data Centers.’ Available on the company’s website, the guide introduces specific power delivery network optimization solutions for AI servers that enhance power stability and reduce power losses across the data center infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203101664/en/ [Murata Manufacturing Co., Ltd.] Technology guide to enhance power stability in AI-driven data centers The guide addresses the rapid advancement and adoption of AI, a trend driving the continuous rollout of new data centers worldwide. As the industry moves toward higher voltage operations and increased equipment density, the resulting increase in overall power consumption has made stable power delivery a critical business issue for data center operators.
The Global Photonics Community Converges in San Francisco as More Than 23,000 Register for Photonics West 20263.2.2026 22:14:00 CET | Press release
The largest annual optics and photonics event highlighted the industry’s best and brightest during a week full of innovation, networking, and research sharing SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical presentations across 100 conferences, 4 stages of industry-focused panels and presentations, 49 courses, and approximately 1,600 exhibitors in the five expos: Photonics West, BiOS, Quantum West, AR | VR | MR, plus, in its inaugural year, Vision Tech. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203925940/en/ Attend
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom